KEY FINDINGS
The North America infertility testing & treatment market is anticipated to grow with a CAGR of 10.48% during the forecasting period of 2021 to 2028. The regional market’s growth is facilitated by the rise in same-sex marriages, the increased age of conception, improved effectiveness of fertility treatments, and changing lifestyles.
MARKET INSIGHTS
The North America infertility testing & treatment market growth analysis entails the study of the United States and Canada. As per the Government of Canada, nearly 16% of couples in Canada experienced infertility in 2019. Besides, this number has increased by roughly 50% since the 1980s. The primary drivers positively impacting the country’s market include the rising number of infertility cases, growing sexually transmitted diseases (STDs), and the surging obese population. According to a recent study, up to 15.7% of Canadian couples are infertile. Since infertility is continually rising in the country, with numerous studies highlighting the trend, the market growth is set to bolster.
The Canadian market’s growth is further accredited to drivers such as the increasing awareness about infertility treatment, the government’s support towards expanding fertility procedures, as well as the availability of reimbursement for the same. In this regard, the Canadian Fertility and Andrology Society (CFAS) and various other private professionals offer fertility clinic guidelines for fertility centers in Canada. As a result, these factors are anticipated to fuel the infertility testing & treatment market growth in North America during the forecasted years.
COMPETITIVE INSIGHTS
Key companies operating in the market are CooperSurgical, Fujifilm Irvine Scientific, EMD Group (Merck KGaA), etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. GROWING STRESS AND LIFESTYLE DISORDERS
3.1.2. INCREASED AGE OF CONCEPTION
3.1.3. INCREASING EFFECTIVENESS OF TREATMENTS
3.1.4. RISING GOVERNMENT SUPPORT
3.2. KEY RESTRAINTS
3.2.1. HIGH COST OF TESTING AND TREATMENT
3.2.2. INFERTILITY CONSIDERED A SOCIAL TABOO
3.2.3. POSSIBLE RISKS ASSOCIATED WITH INFERTILITY TREATMENTS
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON INFERTILITY TESTING & TREATMENT MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY BUYING CRITERIA
4.6.1. TREATMENT OPTIONS
4.6.2. QUALITY OF MEDICAL PROCEDURES
4.6.3. PRICE OF TREATMENTS
4.6.4. SHIFT TOWARDS MEDICAL TOURISM
4.6.5. REIMBURSEMENT
4.7. REGULATORY FRAMEWORK
4.8. VALUE CHAIN ANALYSIS
4.8.1. RAW MATERIAL PROCUREMENT
4.8.2. MANUFACTURING
4.8.3. SUPPLY LOGISTICS
4.8.4. DISTRIBUTION CHANNELS
4.8.5. END-USERS
5. MARKET BY GENDER
5.1. MALE
5.1.1. MALE INFERTILITY TESTING
5.1.1.1. DNA FRAGMENTATION
5.1.1.2. OXIDATIVE STRESS ANALYSIS
5.1.1.3. SPERM PENETRATION ASSAY
5.1.1.4. COMPUTER-ASSISTED SEMEN ANALYSIS (CASA)
5.1.1.5. SPERM AGGLUTINATION
5.1.1.6. MICROSCOPIC EXAMINATION
5.1.1.7. OTHERS
5.1.2. MALE INFERTILITY TREATMENT
5.1.2.1. MEDICATION
5.1.2.2. ASSISTED REPRODUCTIVE TECHNOLOGY & VARICOCELE SURGERY
5.2. FEMALE
5.2.1. FEMALE INFERTILITY TESTING
5.2.1.1. OVULATION TESTING
5.2.1.2. HYSTEROSALPINGOGRAPHY
5.2.1.3. LAPAROSCOPY
5.2.1.4. TRANSVAGINAL ULTRASOUND
5.2.1.5. OVARIAN RESERVE TESTING
5.2.1.6. HORMONAL LEVEL TESTING
5.2.1.7. OTHERS
5.2.2. FEMALE INFERTILITY TREATMENT
5.2.2.1. IVF WITH ICSI
5.2.2.2. IUI
5.2.2.3. IVF WITHOUT ICSI
5.2.2.4. SURROGACY
5.2.2.5. OTHERS
6. MARKET BY END-USER
6.1. FERTILITY AND SURGICAL CENTERS
6.2. HOSPITALS AND RESEARCH LABORATORIES
6.3. CRYOBANKS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. KEY GROWTH ENABLERS
7.1.2. KEY CHALLENGES
7.1.3. KEY PLAYERS
7.1.4. COUNTRY ANALYSIS
7.1.4.1. UNITED STATES
7.1.4.2. CANADA
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGERS & ACQUISITIONS
8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
8.1.3. PARTNERSHIPS & AGREEMENTS
8.2. COMPANY PROFILES
8.2.1. ADORFEM
8.2.2. BANGKOK IVF CENTER
8.2.3. COOK MEDICAL INC
8.2.4. COOPER SURGICAL
8.2.5. CREATE FERTILITY CENTRE
8.2.6. EMD GROUP (MERCK KGAA)
8.2.7. ENDO INTERNATIONAL PLC
8.2.8. ESCO MEDICAL
8.2.9. FERRING PHARMACEUTICALS
8.2.10. FERTILITY FIRST
8.2.11. FUJIFILM IRVINE SCIENTIFIC
8.2.12. GENEA LTD
8.2.13. HALOTECH DNA
8.2.14. HAMILTON THRONE LTD
8.2.15. IVFTECH
8.2.16. LABOTECT GMBH
8.2.17. OLYMPUS CORPORATION
8.2.18. PROGYNY
8.2.19. THERMO FISHER SCIENTIFIC INC
8.2.20. VITROLIFE AB
1. ADORFEM
2. BANGKOK IVF CENTER
3. COOK MEDICAL INC
4. COOPER SURGICAL
5. CREATE FERTILITY CENTRE
6. EMD GROUP (MERCK KGAA)
7. ENDO INTERNATIONAL PLC
8. ESCO MEDICAL
9. FERRING PHARMACEUTICALS
10. FERTILITY FIRST
11. FUJIFILM IRVINE SCIENTIFIC
12. GENEA LTD
13. HALOTECH DNA
14. HAMILTON THRONE LTD
15. IVFTECH
16. LABOTECT GMBH
17. OLYMPUS CORPORATION
18. PROGYNY
19. THERMO FISHER SCIENTIFIC INC
20. VITROLIFE AB
